J&J extends tender offer for Omrix
This article was originally published in Scrip
Johnson & Johnson has extended its $438 million tender offer to buy Omrix Biopharmaceuticals, an Israeli developer of protein-based biosurgery and passive immunotherapies (Scrip Online, November 25th, 2008). The offer, originally due to expire at midnight (Eastern time) tomorrow will now end at midnight (Eastern time) on December 26th. J&J received clearance from the Israeli antitrust authorities earlier this month. The US company has tendered 23.4% of Omrix's common stock on a fully diluted basis to date.
You may also be interested in...
Laura Gonz�lez-Molero will be celebrating her first anniversary as President of Bayer HealthCare Pharmaceuticals, Latin America this month. With Bayer posting total sales of €1.05bnin Latin America in 2014, up 13% over 2013, Ms Gonz�lez-Molero should be pleased with a successful inaugural year. Resolute in her belief that innovation, "part of Bayer's DNA," will determine the company's long-term success in Latin America, rather than growth through acquisition, Ms Gonz�lez-Molero talks to Scrip about her personal ambitions for the company and the region.
A decade since its formation Anvisa, Brazil's medicines regulator, has shaken up the country's framework for ensuring drug quality. Yet the agency's approaches to drug pricing and registration have left some multinationals wanting, reports Sita Shah.
Elan is raising $1.5 billion in bonds to refinance its existing debt and for general corporate purposes, it says.